TY - JOUR T1 - Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice. AU - Sathiya,Sekar, AU - Ranju,Vijayan, AU - Kalaivani,Periyathambi, AU - Priya,Raju Jyothi, AU - Sumathy,Haridass, AU - Sunil,Adoor Gopalan, AU - Babu,Chidambaram Saravana, Y1 - 2013/06/06/ PY - 2013/02/17/received PY - 2013/04/18/revised PY - 2013/05/27/accepted PY - 2013/6/11/entrez PY - 2013/6/12/pubmed PY - 2014/8/15/medline KW - 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine KW - 3,4-dihydroxyphenylacetic acid KW - ANOVA KW - AT1R KW - BDNF KW - CMC KW - DAT KW - DOPAC KW - GDNF KW - GFAP KW - HVA KW - MPTP KW - Motor function KW - PD KW - Parkinson's disease KW - RAS KW - Renin-angiotensin system KW - SEM KW - SNpc KW - ST KW - SYN KW - Striatum KW - TEL KW - TH KW - Telmisartan KW - VMAT2 KW - analysis of variance KW - angiotensin type 1 receptor KW - brain derived neurotrophic factor KW - carboxy methyl cellulose KW - dopamine transporter KW - glial derived neurotrophic factor KW - glial fibrillary acidic proteins KW - homovanillic acid KW - i.p. KW - intraperitoneal KW - standard error of the mean KW - substantia nigra pars compacta KW - tyrosine hydroxylase KW - vesicular monoamine transporter 2 KW - α-synuclein SP - 98 EP - 110 JF - Neuropharmacology JO - Neuropharmacology VL - 73 N2 - Telmisartan (TEL), an angiotensin type 1 receptor (AT1R) antagonist, has been reported to exert neuroprotective effect in animal models of Parkinson's disease (PD). However, its effect on motor functions, mutant protein α-synuclein (SYN) and neurotrophic factors (BDNF and GDNF) expression and their interrelation in PD has not yet been elucidated. In the present study, the effect of TEL on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced motor dysfunctions and dopaminergic degeneration was ascertained through investigating the alterations in protein expression of dopamine transporter (DAT), tyrosine hydroxylase (TH) and SYN in C57BL/6J mouse. Further, the role of TEL on the gene expression of neurotrophic factors such as BDNF and GDNF and protein expression of vesicular monoamine transporter 2 (VMAT2) and Glial fibrillary acidic proteins (GFAP) were studied. In TEL treated mouse, strong negative correlation was observed between motor function and SYN, while a strong positive correlation was noted with BDNF and GDNF expression. TEL caused down-regulation of SYN, GFAP and up-regulation of DAT, TH, VAMT2, BDNF and GDNF expressions. Present data suggest that brain renin angiotensin system (RAS) plays a crucial role in motor function and in the regulation of key proteins such as SYN, BDNF and GDNF, DAT, TH, VMAT2 and GFAP in Parkinsonism. In conclusion, the present study shows that angiotensin type 1 receptor antagonists can ameliorate motor dysfunction and act as potential neuroprotective agent in the management of Parkinsonism. SN - 1873-7064 UR - https://www.unboundmedicine.com/medline/citation/23747572/Telmisartan_attenuates_MPTP_induced_dopaminergic_degeneration_and_motor_dysfunction_through_regulation_of_α_synuclein_and_neurotrophic_factors__BDNF_and_GDNF__expression_in_C57BL/6J_mice_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0028-3908(13)00239-6 DB - PRIME DP - Unbound Medicine ER -